Key Highlights
- Eli Lilly is acquiring AtaiBeckley at $6.75 per share in an all-cash transaction valued at $2.8 billion initially
- ATAI stock climbed 34% during premarket hours Thursday following an initial surge of over 50% after Bloomberg’s report
- The acquisition price reflects a 40% premium over AtaiBeckley’s 30-day volume-weighted average trading price
- Additional contingent payments of up to $2.50 per share could be unlocked through achievement of development and regulatory targets
- The announcement triggered a broader sector rally, with GH Research rising 15% and Compass Pathways gaining 7%
In a major move into the psychedelic medicine space, Eli Lilly has reached an agreement to acquire AtaiBeckley for an initial consideration of $2.8 billion, triggering a 34% surge in ATAI stock during Thursday’s premarket session.
Shares of AtaiBeckley reached $7.19 in premarket trading, marking a 34.2% increase. The stock had initially spiked more than 50% following late Wednesday reports from Bloomberg indicating that Lilly was in advanced negotiations for a premium acquisition.
Under the terms of the agreement, Lilly will pay $6.75 in cash for each AtaiBeckley share. Additionally, shareholders stand to receive contingent consideration of up to $2.50 per share tied to the achievement of specific developmental and regulatory objectives.
The $6.75 offer price delivers a substantial 40% premium compared to AtaiBeckley’s volume-weighted average price calculated over the previous 30 trading days.
Heading into this announcement, ATAI stock had already posted impressive gains of 31% year-to-date through Wednesday’s market close.
A significant portion of ATAI’s 2025 performance occurred in April, when shares surged 22% in a single trading session after President Trump issued an executive directive aimed at accelerating FDA evaluation processes for psychedelic therapies targeting severe mental health conditions.
The company’s flagship candidate, BPL-003, represents an intranasal delivery system for 5-MeO-DMT currently in development as a potential treatment for patients suffering from treatment-resistant depression.
Sector-Wide Rally in Psychedelic Therapeutics
The acquisition announcement created positive momentum across the entire psychedelic drug development sector. In premarket action, GH Research advanced 15%, while Compass Pathways posted a 7% gain. Definium Therapeutics climbed 6%, and Enveric Biosciences increased 3%.
Evan Seigerman, an analyst at BMO Capital Markets, observed that although the transaction could surpass $2 billion in total value, concurrent discussions with additional pharmaceutical companies might drive the final acquisition price higher still.
Brian Abrahams from RBC Capital Markets suggested the psychedelic medicine sector is positioned for continued strength and is gaining mainstream acceptance.
Expanding Lilly’s Neuroscience Portfolio
This acquisition aligns with Lilly‘s strategic pattern of pursuing deals in the neuroscience arena. The pharmaceutical giant’s latest major transaction involved the $7.8 billion acquisition of Centessa Pharmaceuticals, a company focused on sleep disorder treatments.
Lilly’s own shares remained relatively stable Thursday, edging up just 0.3% in premarket trading.
According to LSEG data, AtaiBeckley’s market capitalization was $1.97 billion at Wednesday’s closing bell.
When combining the upfront cash payment with the potential milestone-based payments, the transaction could ultimately reach a total value of $9.25 per share.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
